Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
Inclusion of a substance on the 503A Bulks List does not constitute FDA approval of a drug product and does not establish that the substance is safe or effective
Tirzepatide, approved for T2DM and obesity, achieves data-proven superior glycemic control (HbA1c reductions of 2.02.5%) and weight loss (1520% of body weight) compared to GLP-1 agonists, such as semaglutide [14]
#GLP1 #Semaglutide #ShilingPharma #DrugDelivery #Innovation #ObesityCare #Biopharma #ClinicalTrials #MedTech #ChinaPharma #PeptideTherapy #FutureOfMedicine To view or add a comment, sign in 2025: , , As of 2025, about 4 in 10 commercially insured lives are enrolled in plans using copay accumulators or maximizers
The plot shows the absolute standardized mean difference between the group of patients who initiated GLP-1RA or BI for each variable before and after propensity score matching
